AAPL314.86-2.45 (-0.77%) ▼|ABBV244.78-3.22 (-1.30%) ▼|ABT88.96-3.15 (-3.42%) ▼|ACN134.56-3.96 (-2.86%) ▼|ADBE220.78-9.83 (-4.26%) ▼|AMAT595.70+20.31 (+3.53%) ▲|AMD548.13+13.74 (+2.57%) ▲|AMGN355.25-5.20 (-1.44%) ▼|AMT168.83-0.67 (-0.40%) ▼|AMZN247.49+0.18 (+0.07%) ▲|AVGO389.11+5.06 (+1.32%) ▲|AXP355.06+0.63 (+0.18%) ▲|BA217.11+1.60 (+0.74%) ▲|BAC60.62+1.12 (+1.88%) ▲|BKNG174.85-0.95 (-0.54%) ▼|BLK1,025.44-6.12 (-0.59%) ▼|BMY56.95-2.39 (-4.03%) ▼|BNY154.50+3.23 (+2.14%) ▲|BRK-B491.09-5.76 (-1.16%) ▼|C133.27-7.44 (-5.29%) ▼|CAT933.34+1.87 (+0.20%) ▲|CL91.03-2.18 (-2.34%) ▼|CMCSA23.19-0.78 (-3.25%) ▼|COF205.29+2.27 (+1.12%) ▲|COP111.87-0.98 (-0.87%) ▼|COST921.75-4.68 (-0.51%) ▼|CRM167.56-3.66 (-2.14%) ▼|CSCO117.09-2.16 (-1.81%) ▼|CVS106.18+0.28 (+0.26%) ▲|CVX181.76-0.44 (-0.24%) ▼|DE584.40-1.24 (-0.21%) ▼|DHR199.05-1.11 (-0.55%) ▼|DIS95.87-0.13 (-0.14%) ▼|DUK126.37-0.49 (-0.39%) ▼|EMR136.09+0.71 (+0.52%) ▲|FDX313.66-0.08 (-0.03%) ▼|GD369.50-3.28 (-0.88%) ▼|GE353.73+0.31 (+0.09%) ▲|GEV1,066.01+23.41 (+2.25%) ▲|GILD130.04-1.36 (-1.04%) ▼|GM76.87+0.15 (+0.20%) ▲|GOOG357.33+6.66 (+1.90%) ▲|GOOGL359.51+7.00 (+1.99%) ▲|GS1,140.00+94.09 (+9.00%) ▲|HD337.74+0.63 (+0.19%) ▲|HON222.68+0.43 (+0.19%) ▲|IBM217.07-73.16 (-25.21%) ▼|INTC107.76+4.64 (+4.50%) ▲|INTU282.43-7.33 (-2.53%) ▼|ISRG379.50-27.62 (-6.78%) ▼|JNJ253.85-3.92 (-1.52%) ▼|JPM342.89+8.36 (+2.50%) ▲|KO83.08-1.17 (-1.39%) ▼|LIN522.54-1.52 (-0.29%) ▼|LLY1,152.54-29.33 (-2.48%) ▼|LMT514.99-5.69 (-1.09%) ▼|LOW207.68-0.02 (-0.01%) ▼|LRCX346.10+16.18 (+4.90%) ▲|MA538.02+0.32 (+0.06%) ▲|MCD268.94-3.67 (-1.35%) ▼|MDLZ58.80-1.06 (-1.77%) ▼|MDT79.30-4.27 (-5.11%) ▼|META661.04+4.31 (+0.66%) ▲|MMM156.58-1.12 (-0.71%) ▼|MO70.16-1.71 (-2.38%) ▼|MRK120.78-3.25 (-2.62%) ▼|MS227.67+6.58 (+2.98%) ▲|MSFT384.93-6.06 (-1.55%) ▼|MU983.12+46.12 (+4.92%) ▲|NEE89.54+1.16 (+1.31%) ▲|NFLX73.53-0.30 (-0.41%) ▼|NKE42.86-0.90 (-2.06%) ▼|NOW104.85-6.41 (-5.76%) ▼|NVDA211.80+8.27 (+4.06%) ▲|ORCL127.94-3.60 (-2.74%) ▼|PEP135.45-3.04 (-2.20%) ▼|PFE24.25-0.23 (-0.94%) ▼|PG146.08-2.29 (-1.54%) ▼|PLTR133.72+3.68 (+2.83%) ▲|PM175.95-4.24 (-2.35%) ▼|QCOM178.10-5.88 (-3.20%) ▼|RTX193.39-3.00 (-1.53%) ▼|SBUX106.17-1.17 (-1.09%) ▼|SCHW101.10-1.28 (-1.25%) ▼|SO95.96-0.51 (-0.53%) ▼|SPG221.28+1.79 (+0.82%) ▲|T21.28-0.27 (-1.25%) ▼|TMO534.07+5.56 (+1.05%) ▲|TMUS187.13-1.28 (-0.68%) ▼|TSLA396.18+1.42 (+0.36%) ▲|TXN305.55+6.98 (+2.34%) ▲|UBER72.08-2.18 (-2.94%) ▼|UNH425.19-3.90 (-0.91%) ▼|UNP288.30-0.83 (-0.29%) ▼|UPS113.67+0.78 (+0.69%) ▲|USB62.14-0.20 (-0.32%) ▼|V356.02-1.73 (-0.48%) ▼|VZ42.47-0.21 (-0.49%) ▼|WFC85.29-2.38 (-2.71%) ▼|WMT113.70-1.08 (-0.94%) ▼|XOM145.09+0.58 (+0.40%) ▲|AAPL314.86-2.45 (-0.77%) ▼|ABBV244.78-3.22 (-1.30%) ▼|ABT88.96-3.15 (-3.42%) ▼|ACN134.56-3.96 (-2.86%) ▼|ADBE220.78-9.83 (-4.26%) ▼|AMAT595.70+20.31 (+3.53%) ▲|AMD548.13+13.74 (+2.57%) ▲|AMGN355.25-5.20 (-1.44%) ▼|AMT168.83-0.67 (-0.40%) ▼|AMZN247.49+0.18 (+0.07%) ▲|AVGO389.11+5.06 (+1.32%) ▲|AXP355.06+0.63 (+0.18%) ▲|BA217.11+1.60 (+0.74%) ▲|BAC60.62+1.12 (+1.88%) ▲|BKNG174.85-0.95 (-0.54%) ▼|BLK1,025.44-6.12 (-0.59%) ▼|BMY56.95-2.39 (-4.03%) ▼|BNY154.50+3.23 (+2.14%) ▲|BRK-B491.09-5.76 (-1.16%) ▼|C133.27-7.44 (-5.29%) ▼|CAT933.34+1.87 (+0.20%) ▲|CL91.03-2.18 (-2.34%) ▼|CMCSA23.19-0.78 (-3.25%) ▼|COF205.29+2.27 (+1.12%) ▲|COP111.87-0.98 (-0.87%) ▼|COST921.75-4.68 (-0.51%) ▼|CRM167.56-3.66 (-2.14%) ▼|CSCO117.09-2.16 (-1.81%) ▼|CVS106.18+0.28 (+0.26%) ▲|CVX181.76-0.44 (-0.24%) ▼|DE584.40-1.24 (-0.21%) ▼|DHR199.05-1.11 (-0.55%) ▼|DIS95.87-0.13 (-0.14%) ▼|DUK126.37-0.49 (-0.39%) ▼|EMR136.09+0.71 (+0.52%) ▲|FDX313.66-0.08 (-0.03%) ▼|GD369.50-3.28 (-0.88%) ▼|GE353.73+0.31 (+0.09%) ▲|GEV1,066.01+23.41 (+2.25%) ▲|GILD130.04-1.36 (-1.04%) ▼|GM76.87+0.15 (+0.20%) ▲|GOOG357.33+6.66 (+1.90%) ▲|GOOGL359.51+7.00 (+1.99%) ▲|GS1,140.00+94.09 (+9.00%) ▲|HD337.74+0.63 (+0.19%) ▲|HON222.68+0.43 (+0.19%) ▲|IBM217.07-73.16 (-25.21%) ▼|INTC107.76+4.64 (+4.50%) ▲|INTU282.43-7.33 (-2.53%) ▼|ISRG379.50-27.62 (-6.78%) ▼|JNJ253.85-3.92 (-1.52%) ▼|JPM342.89+8.36 (+2.50%) ▲|KO83.08-1.17 (-1.39%) ▼|LIN522.54-1.52 (-0.29%) ▼|LLY1,152.54-29.33 (-2.48%) ▼|LMT514.99-5.69 (-1.09%) ▼|LOW207.68-0.02 (-0.01%) ▼|LRCX346.10+16.18 (+4.90%) ▲|MA538.02+0.32 (+0.06%) ▲|MCD268.94-3.67 (-1.35%) ▼|MDLZ58.80-1.06 (-1.77%) ▼|MDT79.30-4.27 (-5.11%) ▼|META661.04+4.31 (+0.66%) ▲|MMM156.58-1.12 (-0.71%) ▼|MO70.16-1.71 (-2.38%) ▼|MRK120.78-3.25 (-2.62%) ▼|MS227.67+6.58 (+2.98%) ▲|MSFT384.93-6.06 (-1.55%) ▼|MU983.12+46.12 (+4.92%) ▲|NEE89.54+1.16 (+1.31%) ▲|NFLX73.53-0.30 (-0.41%) ▼|NKE42.86-0.90 (-2.06%) ▼|NOW104.85-6.41 (-5.76%) ▼|NVDA211.80+8.27 (+4.06%) ▲|ORCL127.94-3.60 (-2.74%) ▼|PEP135.45-3.04 (-2.20%) ▼|PFE24.25-0.23 (-0.94%) ▼|PG146.08-2.29 (-1.54%) ▼|PLTR133.72+3.68 (+2.83%) ▲|PM175.95-4.24 (-2.35%) ▼|QCOM178.10-5.88 (-3.20%) ▼|RTX193.39-3.00 (-1.53%) ▼|SBUX106.17-1.17 (-1.09%) ▼|SCHW101.10-1.28 (-1.25%) ▼|SO95.96-0.51 (-0.53%) ▼|SPG221.28+1.79 (+0.82%) ▲|T21.28-0.27 (-1.25%) ▼|TMO534.07+5.56 (+1.05%) ▲|TMUS187.13-1.28 (-0.68%) ▼|TSLA396.18+1.42 (+0.36%) ▲|TXN305.55+6.98 (+2.34%) ▲|UBER72.08-2.18 (-2.94%) ▼|UNH425.19-3.90 (-0.91%) ▼|UNP288.30-0.83 (-0.29%) ▼|UPS113.67+0.78 (+0.69%) ▲|USB62.14-0.20 (-0.32%) ▼|V356.02-1.73 (-0.48%) ▼|VZ42.47-0.21 (-0.49%) ▼|WFC85.29-2.38 (-2.71%) ▼|WMT113.70-1.08 (-0.94%) ▼|XOM145.09+0.58 (+0.40%) ▲|
27 C
New York
Wednesday, July 15, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

China Huadian Backs Central Asia’s Push Toward Sustainable, Low-Carbon Energy

ASTANA, Kazakhstan, June 25, 2025 /PRNewswire/ -- A news report from Xinhuanet: China Huadian Corporation Ltd. is stepping up efforts to support Central Asia's transition to...

Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

MELBOURNE, Australia and INDIANAPOLIS, June 25, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its Telix Manufacturing...

Pan Finance Magazine Announces the Q2 Release and Award Winners of 2025

Pan Finance Magazine’s Q2 2025 edition highlights global market shifts, AI-driven sustainability trends, and announces its prestigious award winners.

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

Amazon’s Largest Data Center: AI-Driven Infrastructure Expansion for Enhanced Computing Capacity

A transformation in data infrastructure is underway with Amazon's construction of a substantial data center network in New Carlisle, Indiana. This 1,200-acre development, which...

White House Tech Leaders Threaten Innovation—Evaluating Long-Term Investment Risks

The role of American universities in driving entrepreneurial success is indisputable, particularly in their contribution to foundational technologies and medical advancements. This direct link...

£7.5 million Longitude Prize on ALS launches

LONDON, June 25, 2025 /CNW/ -- The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to incentivise and reward cutting...

ECARX Secures Non-Automotive Customer for its Lidar Solution, Expanding into the High-Growth Robotics Market

Partnership with leading robotic lawn mower developer marks strategic diversification beyond automotive intelligence sector 
Partnership with leading robotic lawn mower developer marks strategic diversification beyond automotive intelligence sector

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

Elektrobit and global partner to jointly develop EV.OS – an AI-centric automotive platform for software-defined vehicles

AI-centric, smart automotive platform will accelerate the transition towards software-defined mobility. ERLANGEN, Germany, June 25, 2025 /PRNewswire/ -- Elektrobit today announced the signing of a joint...

Novo Nordisk Foundation and University of Copenhagen announce USD 109 million grant to new Danish research centre to make designed proteins with vast potential

COPENHAGEN, Denmark, June 25, 2025 /PRNewswire/ -- Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to...

Novo Nordisk Foundation and University of Copenhagen announce USD 109 million grant to new Danish research centre to make designed proteins with vast potential

COPENHAGEN, Denmark, June 25, 2025 /PRNewswire/ -- Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers